



JC10 Rec'd PCT/PTO 1 4 FEB

PATENT APPLICATION DOCKET NO.:

00537-190002

Technology Center 2600

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Barry A. Morgan and Dean Sadat-Aalaee

Date of Deposit:

Application No.: 09/980,133

Group Art Unit: Unknown

Filed:

November 27, 2001

Examiner:

Unknown

Title:

NEUROMEDIN B AND SOMATOSTATIN RECEPTOR AGONISTS

## **CERTIFICATE OF MAILING**

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

Karen Louden

INFORMATION DISCLOSURE STATEMENT AND AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT

	nt Commissioner for Patents ngton, D.C. 20231						
Sir:	S,						
This In	formation Disclosure Statement is submitted:						
[]	under 37 CFR 1.129(a), or (First/Second submission after Final Rejection)						
[X]	under 37 CFR 1.97(b), or (Within three months of filing national application; or date of entry of the national stage in international application; or before mailing date of first office action on the merits; whichever occurs last)						
[]	under 37 CFR 1.97(c) together with either:						
	[ ] a Statement under 37 CFR 1.97(e), as checked below, or						
	[ ] a \$240.00 fee under 37 CFR 1.17(p), or  (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)						
[ ]	under 37 CFR 1.97(d) together with:						
	[ ] a Statement under 37 CFR 1.97(e), as checked below, and						
	a Petition under 37 CFR 1.97(d)(2), and						
	[ ] a \$130.00 petition fee set forth in 37 CFR 1.17(i).  (Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)						
[]	Applicant requests that the attached IDS and cited reference(s) [ ] be placed in the application filewrapper. (Filed after payment of issue fee)						
[ X ]	The listed references were cited in the enclosed Search Report which issued in connection with the corresponding International Patent Application.						

## Statement Under 37 CFR 1.97(e)

[ ]	foreign	of information contained in this Information Disclosure Statement was cited in a communication from a patent office in a counterpart foreign application not more than three months prior to the filing of this tion Disclosure Statement; or							
[]	foreign reasonal								
[ X ]	Enclose	d herewith is form PTO-1449, with copies of the references noted thereon.							
[]	Copies of the reference(s) noted on the enclosed form 1449 were previously cited by or submitted to the Patent and Trademark Office in connection with U.S. Application Serial No. [ ], from which the present application claims benefit under 35 U.S.C. § 120 (37 C.F.R. 1.98(d)).								
Concise	e Explana	tion Requirement (non-English references):							
[ X ]	The "concise explanation" requirement for reference(s) WO99 25729 under 37 CFR 1.98(a)(3) is satisfied by EP 1 033 372 A1:								
	[ ]	the explanation provided on the attached sheet.							
	[ ]	the explanation provided in the Specification.							
	[X]	submission of the enclosed International Search Report.							
	[ ]	the enclosed English language abstracts.							
enclose	uested the d form P 1302.12)	at the information disclosed herein be made of record in this application, and that the references listed on the IO-1449 appear under the "References Cited" heading of any Patent which issues from this application,							
Method	l of paym	ent:							
[ ]	A check	for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply.							
[X ]	Commi	fee is believed to be due for this submission. However Applicant(s) hereby authorize the Assistant mmissioner to charge any fees that may be deemed to be due or to credit any overpayment to Deposit Account . 50-0590. Two copies of this Statement are enclosed.							
[X]	The Assistant Commissioner is hereby authorized to please charge any deficiency in fees and credit any overpaymen to Deposit Account 50-0590. Two copies of this Statement are enclosed.								
Dated:	1/2	Respectfully submitted, BIOMEASURE, INCORPORATED  BLAND JOHN Alan F. Feeney, Attorney for Applicant(s) Registration No.: 43,609 Telephone: (508) 478-0144 Facsimile: (508) 473-3531							

27 Maple Street Milford, Massachusetts 01757

EXAMINER

ΑK

DATE CONSIDERED

EXPERIMENTAL, (1996), Vol. 45, no 8 Suppl.1, pgs. 42-45 XP002149617

Subtypes on Human Endocrine Tumors", METABOLISM CLINICAL AND

ATTORNEY DOCKET 00537-190002

APPLICATION NO. 09/980,133

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

APPLICANT

Barry A. Morgan & Dean Sadat-Aalaee

		Importanti chasta de s	0000007741	Barry A. Morgan & Dean Sadat-Aalaee			
FEB 1 4 2002 U.S. PATE				FILING DATE November 27, 2001 Unknown			
FEB	1 4 00		U.S. PATE	ENT DOCUMENTS			
EXAM- INI- INI- TIAL	\$ T3/65	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
			FOREIGN PA	TENT DOCUMENTS			
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	АĻ	0 395 417 A1	Apr. 26, 90	Europe			
V	AM	0 395 417 B1	Apr. 26, 90	Europe			
V	AN	1 033 372 A1	Nov. 18, 98	Europe			
		OTHER DOCUMENTS	(Including Author	, Title, Date, Pertinen	t Pages,	Etc.)	
	(A)						
							, 14, 144
EXAMIN	NER			DATE CONSIDERED			